Price: $29.35, Change: $-1.64, Percent Change: -5.29%
Related Articles
Research
Research Alert: CFRA Keeps Sell Opinion On Shares Of Murphy Oil Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $2 to $31, reflecting a combination of our DCF and relative valuation models. On a relative basis, we apply a 4.0x multiple of enterprise value to projected 2027 EBITDA, slightly below peers, but we think a discounted multiple is reasonable, as we see a narrower surplus of operating cash flow to handle capex requirements than do most peers. This approach yields a value of $26 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 4% per year, terminal growth of 2%, discounted at a WACC of 6.1%, yields intrinsic value of $37 per share. We lift our 2026 EPS estimate by $2.56 to $3.89 but lower 2027's by $0.18 to $1.85. We see possible risk in 2027 from a commodity price downturn, which could crimp growth in capex spending, or growth in returns to shareholders. Our estimates for 2027 are a fair bit lower than consensus, which has less to do with company-specific factors, and more to do with our take on the macroeconomic view of crude oil prices.
$MUR
Research
Research Alert: Dox Posts In-line Quarter, Modest Backlog Growth; Maintains Fy 26 Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DOX's Mar-Q results slightly exceeded expectations, with sales of $1.172B (+3.9% Y/Y) and non-GAAP EPS of $1.78 beating consensus views of $1.166B and $1.76, respectively. Constant currency sales growth again decelerated, coming in at 2.2% from the prior quarter's 3.5% rate, with managed services (65% of sales) slowing to 1.6% growth from 2.3% growth in Q1. Management narrowed its FY 26 guidance ranges, with sales growth now expected at 2.6%-4.6% (vs. prior 1.5%-5.5%) and EPS growth expected at 5%-7% (vs. prior 4%-8%). 12-month backlog grew 2.6% Y/Y to $4.28B, offering strong support for the company's modest sales growth outlook with minimal reliance on shorter-term discretionary work (which has been under pressure amid the uncertain macro environment). CFO Tamar Rapaport-Dagin will be leaving the company, with Tal Rozenfeld (Head of Finance) taking over effective June 2026, though we expect no material operating impact from the change.
$DOX
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Unitedhealth Group
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $440 from $385, 24x our 2026 EPS estimate (up $0.11 to $18.36; 2027 estimate up $0.64 to $20.76), a premium to UNH's 10-year historical forward average of 19.4x. Our target multiple is above most peers to reflect strong FCF generation, balance sheet strength, scale advantages, and a diversified business model across health insurance, pharmacy benefit management, health care technology and analytics, and outpatient facility networks. We are upgrading our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with UNH and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve.
$UNH